The article recapitulates some of the historical facts that led up to the recognition of dopamine (DA) as a biologically active substance in the brain and its crucial role in Parkinson's disease (PD). Three events to which the writer has been an eyewitness are specially highlighted and placed in their proper historical perspective: (1) the discovery of the striatal DA deficit in the PD brain; (2) the development of the DA replacement treatment with L-dopa, and (3) the 'birth' of the nigrostriatal DA pathway. The opposition to the new observations and their unexpected and far-reaching consequences will be illustrated by briefly discussing the strongly negative opinions expressed by some famous brain scientists of the day about the relationship between the substantia nigra, PD, and the DA-containing nigrostriatal fiber connection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000113678 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Validating the Accuracy of Parkinson's Disease Clinical Diagnosis: A UK Brain Bank Case-Control Study.
Ann Neurol
January 2025
Research Unit of Neurology, Neurophysiology and Neurobiology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.
Objective: Despite diagnostic criteria refinements, Parkinson's disease (PD) clinical diagnosis still suffers from a not satisfying accuracy, with the post-mortem examination as the gold standard for diagnosis. Seminal clinicopathological series highlighted that a relevant number of patients alive-diagnosed with idiopathic PD have an alternative post-mortem diagnosis. We evaluated the diagnostic accuracy of PD comparing the in-vivo clinical diagnosis with the post-mortem diagnosis performed through the pathological examination in 2 groups.
View Article and Find Full Text PDFDual-task-related gait patterns as possible marker of precocious and subclinical cognitive alterations in Parkinson disease.
Sci Rep
January 2025
Department of Medicine, Surgery and Dentistry, Center for Neurodegenerative Diseases (CEMAND), University of Salerno, Fisciano, Italy.
Subtle gait and cognitive dysfunction are common in Parkinson's disease (PD), even before most evident clinical manifestations. Such alterations can be assumed as hypothetical phenotypical and prognostic/progression markers. To compare spatiotemporal gait parameters in PD patients with three cognitive status: cognitively intact (PD-noCI), with subjective cognitive impairment (PD-SCI) and with mild cognitive impairment (PD-MCI) in order to detect subclinical gait differences.
View Article and Find Full Text PDFSplicing accuracy varies across human introns, tissues, age and disease.
Nat Commun
January 2025
UK Dementia Research Institute, University of Cambridge, Cambridge, United Kingdom.
Alternative splicing impacts most multi-exonic human genes. Inaccuracies during this process may have an important role in ageing and disease. Here, we investigate splicing accuracy using RNA-sequencing data from >14k control samples and 40 human body sites, focusing on split reads partially mapping to known transcripts in annotation.
View Article and Find Full Text PDFAttention-deficit/hyperactivity disorder-related psychomotor activity and altered neuronal activity in the medial prefrontal cortex and striatum in the A53T mouse model of Parkinson's disease and other synucleinopathies: Findings from an "endophenotype" approach.
Prog Neuropsychopharmacol Biol Psychiatry
January 2025
Laboratory of Molecular Neurobiology and Behavior, Department of Neurobiology, Institute for Biological Research "Siniša Stanković" - National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia. Electronic address:
Attention-Deficit/Hyperactivity Disorder (ADHD) is associated with an increased risk of Parkinson's disease (PD) and other synucleinopathies later in life. The severity of the ADHD phenotype may play a significant role in this association. There is no indication that any of the existing animal models can unify these disorders.
View Article and Find Full Text PDFCOMPARING DIRECTIONAL AND OMNIDIRECTIONAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE PATIENTS.
Stereotact Funct Neurosurg
January 2025
Introduction: In 2015, directional leads have been released in Europe for deep brain stimulation (DBS) and have been particularly used for subthalamic nucleus (STN) DBS for Parkinson's disease (PD). In this study we aimed to compare an omnidirectional and directional leads cohort of PD patients when it comes to clinical effectiveness and to assess the correlation with volume of tissue activated - target overlap (VTA-target).
Methods: A total of 60 consecutive patients were retrospectively included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!